Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Arthritis & Rheumatism

• Publication date

  2012-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/art.34488PMID 22488501
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment.

  2011cited by this paper
• HLA-B58 can help the clinical decision on starting allopurinol in patients with chronic renal insufficiency.

  2011cited by this paper
• Relationship Between Serum Urate and Plasma Oxypurinol in the Management of Gout: Determination of Minimum Plasma Oxypurinol Concentration to Achieve a Target Serum Urate Level

  2011cited by this paper
• Influence of antihyperuricemic therapy on the clinical and radiographic progression of gout.

  2010cited by this paper
• Strong association between HLA-B*5801 and allopurinol-induced Stevens–Johnson syndrome and toxic epidermal necrolysis in a Thai population

  2009cited by this paper
• HLA-B allele associations with certain drugs are not confirmed in Japanese patients with severe cutaneous drug reactions.

  2008cited by this paper
• A European study of HLA-B in Stevens–Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs

  2008cited by this paper
• HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis.

  2008cited by this paper
• British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout.

  2007cited by this paper
• Allopurinol Dosing in Renal Impairment: Walking the Tightrope Between Adequate Urate Lowering and Adverse Events

  2007cited by this paper
• EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee For International Clinical Studies Including Therapeutics (ESCISIT)

  2006cited by this paper
• Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout.

  2006cited by this paper
• Erratum: HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol (Proceedings of the National Academy of Sciences of the United States of America (March 15, 2005) 102, 11 (4134-4139))

  2005cited by this paper
• HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol.

  2005cited by this paper
• Fatal allopurinol hypersensitivity syndrome after treatment of asymptomatic hyperuricaemia

  2005cited by this paper
• Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis.

  2004cited by this paper
• Quality of care indicators for gout management.

  2004cited by this paper
• A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy.

  2004cited by this paper
• Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout.

  2002cited by this paper
• Relation between adverse events associated with allopurinol and renal function in patients with gout

  2001cited by this paper
• A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation

  1999cited by this paper
• Cell-mediated immunity in allopurinol-induced hypersensitivity.

  1994cited by this paper
• Allopurinol Hypersensitivity Syndrome: A Review

  1993cited by this paper
• Some adverse reactions to allopurinol may be mediated by lymphocyte reactivity to oxypurinol.

  1988cited by this paper
• Plasma oxipurinol concentrations during allopurinol therapy.

  1987cited by this paper
• Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency.

  1984cited by this paper
• Allopurinol hepatotoxicity. Report of two cases and review of the literature.

  1981cited by this paper
• Acute adverse reactions attributed to allopurinol in hospitalised patients.

  1981cited by this paper
• The allopurinol hypersensitivity syndrome.

  1979cited by this paper
• Severe Hypersensitivity Reactions to Allopurinol

  1979cited by this paper
• Severe hypersensitivity reactions to allopurinol.

  1979cited by this paper
• Allopurinol hypersensitivity: Granular deposition of IgM at the dermal-epidermal junction

  1976cited by this paper

• Development of a non-genetic risk prediction model for allopurinol-induced severe cutaneous adverse drug reactions: a multicenter retrospective observational study.

  2026cites this paper
• Allopurinol-Related Severe Cutaneous Adverse Reactions: A Narrative Review

  2026cites this paper
• 49-Year-Old Man With Subjective Fevers and Low Back Pain.

  2026cites this paper
• Allopurinol‐Induced Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: A Systematic Review of Case Reports and Case Series

  2025cites this paper
• Gout Management in Patients With CKD.

  2025cites this paper
• Gout therapy updated

  2025cites this paper
• Long‐term remission in gout: Challenges and future opportunities

  2025cites this paper
• Allopurinol hypersensitivity is rare, bad, and partially avoidable, but allopurinol can still be used effectively

  2025cites this paper
• Perspectives on the Management of Hyperuricemia and Gout in Older Adults.

  2025cites this paper
• Management of gout in advanced renal disease

  2025cites this paper
• KDOQI US Commentary on the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of CKD.

  2024influential citation
• Comparative Risk of Gout Flares When Initiating or Escalating Various Urate‐Lowering Therapy: A Systematic Review With Network Meta‐Analysis

  2024cites this paper
• The development and evaluation of dose‐prediction tools for allopurinol therapy (Easy‐Allo tools)

  2024cites this paper
• Effects and mechanisms of kidney bean peptides on uric-lowering activity in oteracil potassium-induced hyperuricemia rats

  2024cites this paper
• [Gout, beyond the joint: How should we treat it?]

  2024cites this paper
• What Is Allopurinol Failure and What Should We Do About It?

  2024cites this paper
• The Association between High-Dose Allopurinol and Erythropoietin Hyporesponsiveness in Advanced Chronic Kidney Disease: JOINT-KD Study

  2024cites this paper
• Efficacy and Safety of Allopurinol and Febuxostat in Patients With Gout and CKD: Subgroup Analysis of the STOP Gout Trial.

  2024cites this paper
• Gout and its management

  2024cites this paper
• Safety and efficacy of gout treatments in people with renal impairment

  2024cites this paper
• Easing the way to achieving target serum urate in people with gout: protocol for a non-inferiority randomised strategy trial using an allopurinol dosing model in Aotearoa/New Zealand (the Easy-Allo Study)

  2024cites this paper
• Current issues in the practical use of allopurinol in patients with gout and hyperuricemia

  2024cites this paper
• Targeting Neutrophil Extracellular Traps in Gouty Arthritis: Insights into Pathogenesis and Therapeutic Potential

  2024cites this paper
• Year in Review 2023: Gout Clinical Research

  2024cites this paper
• Yet More Reassurance: Treat-to-Target With Allopurinol or Febuxostat is Safe and Effective in Lowering Serum Urate in People With CKD.

  2024cites this paper
• The Singapore Experience With Uncontrolled Gout: Unmet Needs in the Management of Patients

  2023cites this paper
• Management of Patients with Gout and Kidney Disease: A Review of Available Therapies and Common Missteps.

  2023cites this paper
• The Hong Kong Society of Rheumatology consensus recommendations for the management of gout

  2023cites this paper
• BIOATCTIVITY OF PHLORETIN FROM Syzgium polyanthum (WIGHT) WALP AS A GOUTY ARTHRITIS TREATMENT BASED ON SCREENING IN SILICO

  2023cites this paper
• Impact of pharmacist-led collaborative gout clinic on timely achievement of serum uric acid goals

  2023cites this paper
• Reframing Gout Management to Empower Those Who Need It Most

  2023cites this paper
• Is colchicine prophylaxis required with start-low go-slow allopurinol dose escalation in gout? A non-inferiority randomised double-blind placebo-controlled trial

  2023cites this paper
• Population pharmacokinetics, pharmacodynamics and pharmacogenetics modelling of oxypurinol in Hmong adults with gout and/or hyperuricemia

  2023cites this paper
• Pharmacogenetic Perspective for Optimal Gout Management

  2022cites this paper
• Safety and efficacy of SHR4640 combined with febuxostat for primary hyperuricemia: a multicenter, randomized, double-blind, phase II study

  2022cites this paper
• Pharmacological overview for therapy of gout and hyperuricemia

  2022cites this paper
• Egyptian consensus on treat-to-target approach of gout: evidence-based clinical practice guidelines for the management of gout

  2022cites this paper
• Management and Cure of Gouty Arthritis.

  2022cites this paper
• The effect of allopurinol on cardiovascular outcomes in patients with type 2 diabetes: a systematic review

  2022cites this paper
• Docking Studies of Potent Xanthine Oxidase Inhibitors-Molecules Patented and Published from 2011-2020

  2022cites this paper
• A Drug–Drug Interaction Study of a Novel Selective Urate Reabsorption Inhibitor, SHR4640, and Xanthine Oxidase Inhibitor, Febuxostat, in Patients With Primary Hyperuricemia

  2022cites this paper
• Considerations for Choosing First-Line Urate-Lowering Treatment in Older Patients with Comorbid Conditions.

  2022cites this paper
• Acylation of Anthocyanins and Their Applications in the Food Industry: Mechanisms and Recent Research Advances

  2022cites this paper
• How to Take a Good Clinical History in Cases of Allergic Reactions to Medications.

  2022cites this paper
• Therapeutics in rheumatology and the kidney.

  2022cites this paper
• Measuring quality of gout management in residential aged care facilities

  2022cites this paper
• Initiation Dose of Allopurinol and the Risk of Severe Cutaneous Reactions in Older Adults With CKD: A Population-Based Cohort Study.

  2022cites this paper
• Clinical features, treatment outcomes and prognostic factors of allopurinol‐induced DRESS in 52 patients

  2022cites this paper
• Available treatment options for hyperuricemic patients

  2021cites this paper
• Update on gout management: what is old and what is new

  2021cites this paper
• What’s new on the front-line of gout pharmacotherapy?

  2021cites this paper
• Gout flare in the critical care setting: diagnostic challenges and treatment options

  2021cites this paper
• Early versus Late Allopurinol Initiation in Acute Gout Flare (ELAG): a randomized controlled trial

  2021cites this paper
• Predominant HLA Alleles and Haplotypes in Mild Adverse Drug Reactions Caused by Allopurinol in Vietnamese Patients with Gout

  2021cites this paper
• Anti-gout Medications and Risk of Cardiovascular Disease: A Nested Case-Control Study

  2021cites this paper
• Management of gout in chronic kidney disease: a G-CAN Consensus Statement on the research priorities

  2021cites this paper
• Association of urate‐lowering drugs with the risk of future urolithiasis in patients with gout: A population‐based nested case–control study

  2021cites this paper
• Treatment advances in gout.

  2021cites this paper
• 60-Year-Old Woman With Acute-Onset Knee Pain.

  2021cites this paper
• Efficacy and safety of urate-lowering therapy in people with kidney impairment: a GCAN-initiated literature review.

  2021cites this paper
• Management and Cure of Gouty Arthritis.

  2021cites this paper
• Genetic Markers for Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis in the Asian Indian Population: Implications on Prevention

  2021cites this paper
• Therapeutic Strategies for the Treatment of Chronic Hyperuricemia: An Evidence-Based Update

  2021cites this paper
• Managing hyperuricemia and gout in chronic kidney disease: a clinical conundrum

  2021cites this paper
• An Overview on the Role of Xanthine Oxidase Inhibitors in Gout Management

  2021cites this paper
• Association Between Use of Anti-gout Preparations and Dementia: Nested Case–Control Nationwide Population-Based Cohort Study

  2021cites this paper
• Gout.

  2021cites this paper
• La maladie goutteuse

  2020cites this paper
• 2020 American College of Rheumatology Guideline for the Management of Gout

  2020cites this paper
• Recent approaches to gout drug discovery: an update

  2020cites this paper
• Hyperuricaemia in primary care

  2020cites this paper
• Is HLA-B*58:01 genotyping cost effective in guiding allopurinol use in gout patients with chronic kidney disease?

  2020cites this paper
• [Gout].

  2020cites this paper
• Allopurinol hypersensitivity: Pathogenesis and prevention.

  2020cites this paper
• Rheumatic Disease in Geriatrics: Diagnosis and Management

  2020cites this paper
• Hypersensitivity reactions with allopurinol and febuxostat: a study using the Medicare claims data

  2020cites this paper
• Pharmacogenomics: An evolving clinical tool for precision medicine

  2020cites this paper
• The Management of Gout in Renal Disease.

  2020cites this paper
• Commentaries on the updated American College of Rheumatology guidelines for the management of gout. Urate-lowering drugs (Part 1)

  2020cites this paper
• HLA-B*58:01 carrier status of Hmong in Minnesota: first in Hmong genotyping for prevalence of this biomarker of risk for severe cutaneous adverse reactions caused by allopurinol

  2020cites this paper
• Clinical Effects of Xanthine Oxidase Inhibitors in Hyperuricemic Patients

  2020cites this paper
• Xanthine oxidase inhibitors: patent landscape and clinical development (2015–2020)

  2020cites this paper
• Risk factors for cutaneous reactions to allopurinol in Kinh Vietnamese: results from a case-control study

  2020cites this paper
• Renal effects of uric acid: hyperuricemia and hypouricemia

  2020cites this paper
• Hyperurikemie v ambulanci praktického lékaře

  2020cites this paper
• Correspondence to ‘Hypersensitivity reactions with allopurinol and febuxostat: a study using the Medicare claims data’

  2020cites this paper
• Hyperuricemia As a trigger of Immune Response in Hypertension and Chronic Kidney Disease.

  2020cites this paper
• A nurse‐led, rheumatologist‐assisted telemedicine intervention for dose escalation of urate‐lowering therapy in gout

  2020cites this paper
• Successful Desensitization to Febuxostat in a Patient With Hypersensitivity to Allopurinol and Febuxostat and Review of the Literature.

  2020cites this paper
• Crystal Arthropathy in the Elderly Population

  2020cites this paper
• Highly Acylated Anthocyanins from Purple Sweet Potato ( Ipomoea batatas L.) Alleviate Hyperuricemia and Kidney Inflammation in Hyperuricemic Mice: Possible Attenuation Effects on Allopurinol.

  2019cites this paper
• The role of febuxostat in gout

  2019cites this paper
• Risk of cutaneous adverse reactions associated with allopurinol or febuxostat in real‐world patients: A nationwide study

  2019cites this paper
• Examining the use of allopurinol: Perspectives from recent drug injury relief applications.

  2019cites this paper
• Pharmacological urate-lowering approaches in chronic kidney disease.

  2019cites this paper
• A zebrafish (danio rerio) model for high-throughput screening food and drugs with uric acid-lowering activity.

  2019cites this paper
• Adherence and Outcomes with Urate-Lowering Therapy: A Site-Randomized Trial.

  2019cites this paper
• Epidemiology and risk factors for severe delayed drug hypersensitivity reactions.

  2019cites this paper
• Gout Management in Chronic Kidney Disease: Pearls and Pitfalls

  2019cites this paper
• Acute kidney injury associated with febuxostat and allopurinol: a post-marketing study

  2019cites this paper